Cardiff Oncology Inc (NASDAQ:CRDF) — Market Cap & Net Worth
Market Cap & Net Worth: Cardiff Oncology Inc (CRDF)
Cardiff Oncology Inc (NASDAQ:CRDF) has a market capitalization of $92.29 Million ($92.29 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19576 globally and #4481 in its home market, demonstrating a 23.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cardiff Oncology Inc's stock price $1.35 by its total outstanding shares 68364979 (68.36 Million). Also see balance sheet size of Cardiff Oncology Inc for a full breakdown of the balance sheet.
Cardiff Oncology Inc Market Cap History: 2015 to 2026
Cardiff Oncology Inc's market capitalization history from 2015 to 2026. Data shows change from $26.58 Billion to $92.29 Million (-40.69% CAGR). Also see how efficiently does Cardiff Oncology Inc generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Cardiff Oncology Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #556 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1887 of 3165 |
Weight: Cardiff Oncology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cardiff Oncology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cardiff Oncology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CRDF share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
323.96x
Cardiff Oncology Inc's market cap is 323.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $10.34 Billion | $381.00K | -$39.20 Million | 27130.67x | N/A |
| 2017 | $1.53 Billion | $505.00K | -$24.91 Million | 3021.60x | N/A |
| 2018 | $217.40 Million | $378.00K | -$16.46 Million | 575.13x | N/A |
| 2019 | $84.77 Million | $244.63K | -$16.41 Million | 346.53x | N/A |
| 2020 | $1.23 Billion | $366.00K | -$19.31 Million | 3360.34x | N/A |
| 2021 | $410.87 Million | $359.00K | -$28.29 Million | 1144.49x | N/A |
| 2022 | $95.71 Million | $386.00K | -$38.70 Million | 247.96x | N/A |
| 2023 | $101.18 Million | $488.00K | -$41.44 Million | 207.34x | N/A |
| 2024 | $296.70 Million | $683.00K | -$45.43 Million | 434.41x | N/A |
| 2025 | $192.11 Million | $593.00K | -$45.88 Million | 323.96x | N/A |
Competitor Companies of CRDF by Market Capitalization
Companies near Cardiff Oncology Inc in the global market cap rankings as of September 18, 2026. Review Cardiff Oncology Inc (CRDF) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cardiff Oncology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Cardiff Oncology Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Cardiff Oncology Inc's market cap moved from $26.58 Billion to $ 92.29 Million, with a yearly change of -40.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $92.29 Million | -51.96% |
| 2025 | $192.11 Million | -35.25% |
| 2024 | $296.70 Million | +193.24% |
| 2023 | $101.18 Million | +5.71% |
| 2022 | $95.71 Million | -76.71% |
| 2021 | $410.87 Million | -66.59% |
| 2020 | $1.23 Billion | +1350.81% |
| 2019 | $84.77 Million | -61.01% |
| 2018 | $217.40 Million | -85.75% |
| 2017 | $1.53 Billion | -85.24% |
| 2016 | $10.34 Billion | -61.11% |
| 2015 | $26.58 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Cardiff Oncology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $92.29 Million USD |
| MoneyControl | $92.29 Million USD |
| MarketWatch | $92.29 Million USD |
| marketcap.company | $92.29 Million USD |
| Reuters | $92.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more